SCHEMBL3174582

SCHEMBL3174582

CC(C)(C)OC(=O)NN(c1nc(Cl)ncc1Cl)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.44
STK17A Q9UEE5 1/20 0.44
ATR Q13535 1/20 0.35
BTK Q06187 2/20 0.35
JAK3 P52333 1/20 0.35
CACNA1B Q00975 2/20 0.34
NFKB1 P19838 2/20 0.34
ATF1 P18846 1/20 0.34
CDK9 P50750 1/20 0.33
GAA P10253 1/20 0.33
CNR2 P34972 1/20 0.33
EPHX1 P07099 1/20 0.33
KMT2A Q03164 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
S1PR1 P21453 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3168722 0.99 STK17B (0.45) STK17BSTK17AATRBTKJAK3
SCHEMBL3176966 0.90 STK17B (0.42) STK17BSTK17AATRBTKJAK3
SCHEMBL3169517 0.89 STK17B (0.38) STK17BSTK17AATRBTKJAK3
SCHEMBL3174379 0.88 STK17B (0.39) STK17BSTK17AATRBTKJAK3
SCHEMBL3165883 0.86 JAK3 (0.40) STK17BSTK17AATRBTKJAK3
SCHEMBL3169244 0.85 JAK3 (0.40) STK17BSTK17AATRBTKJAK3
SCHEMBL13525095 0.83 TSHR (0.33) STK17BSTK17ANFKB1ATF1KMT2A
SCHEMBL5302024 0.81 STK17B (0.44) STK17BSTK17ABTKJAK3CACNA1B
SCHEMBL3169120 0.80 STK17B (0.36) STK17BSTK17AATRBTKJAK3
SCHEMBL3319192 0.78 CDK1 (0.43) KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
EP-2077841-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited (GB) 2009-07-15 EP disclosed
EP-2030621-A1 Novel substituted pyrimidines as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-03-04 EP disclosed
EP-2030621-A1 Novel substituted pyrimidines as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-03-04 EP disclosed
EP-1947091-A1 Pyrimidyl nitrile derivatives as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
EP-1947091-A1 Pyrimidyl nitrile derivatives as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
WO-2008052934-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed
WO-2008052934-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS SERPINB1, CTRL, PRSS1 STK17B 1868/4885STK17A 1990/4885ATR 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.